Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. [electronic resource]
Producer: 20010412Description: 1031-7 p. digitalISSN:- 0028-4793
- Adult
- Aged
- Antineoplastic Agents -- administration & dosage
- Benzamides
- Blood Cell Count
- Dose-Response Relationship, Drug
- Enzyme Inhibitors -- administration & dosage
- Female
- Fusion Proteins, bcr-abl -- antagonists & inhibitors
- Humans
- Imatinib Mesylate
- Interferon-alpha -- therapeutic use
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive -- blood
- Male
- Middle Aged
- Phosphorylation
- Piperazines -- administration & dosage
- Protein-Tyrosine Kinases -- antagonists & inhibitors
- Pyrimidines -- administration & dosage
- Recurrence
- Remission Induction -- methods
No physical items for this record
Publication Type: Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
There are no comments on this title.
Log in to your account to post a comment.